Clinical Trial Update: Lipid-lowering Therapy for Secondary Prevention in Patients Undergoing Elective Percutaneous Coronary Intervention (PCI)

View source ↗

Summary

A trial evaluating rosuvastatin for secondary prevention in patients undergoing elective percutaneous coronary intervention has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Rosuvastatin (rosuvastatin)

Snippet

Sponsor: AstraZeneca | Conditions: Coronary Artery Disease | Status: TERMINATED